12:21 PM EST, 11/17/2025 (MT Newswires) -- Novo Nordisk ( NVO ) on Monday lowered the prices of its Wegovy obesity drug and Ozempic diabetes treatment for self-paying patients in the US, following a recent agreement with the Trump Administration to expand access to the products.

The Danish drugmaker said it will cut the direct-to-patient prices of Wegovy and Ozempic to $349 per month from $499, effective Monday.

The company is offering the two lowest doses of these drugs to new self-pay patients at a limited time price of $199 per month through March 31. The offer is available only for the first two months of therapy.

Novo Nordisk ( NVO ) said the self-pay cost of a 2 mg dose of Ozempic will remain at $499 per month.

Earlier this month, the drugmaker agreed to slash Wegovy and Ozempic prices under the upcoming TrumpRx program, according to a statement by the White House. Novo Nordisk ( NVO ) said at the time that it expects to receive a tariff exemption for three years as a result of the deal with the Trump administration.

"The US healthcare system is complex, with different types of insurance and various ways for patients to obtain their medicines," Novo Nordisk's ( NVO ) executive vice president of US operations, Dave Moore, said in the Monday statement. "Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay."

In November, the Drugmaker reported third-quarter earnings of 4.50 kroner ($0.70) per share, down from 6.12 kroner a year earlier. Sales improved to 74.98 billion kroner from 71.31 billion kroner.

At the time, the company lowered the top end of its full-year sales growth outlook due to reduced growth expectations for its glucagon-like peptide-1 treatments within diabetes and obesity.

Novo Nordisk's ( NVO ) New York Stock Exchange-listed shares rose 1.7% in midday trading. The stock has lost 43% so far this year.

Price: 48.96, Change: +0.70, Percent Change: +1.45